Skip to main content

Security report for novartis.pl

Novartis Poland · Healthcare · Poland

Low risk. 5 critical or high findings in Security headers, GDPR outside view and 1 other check.

Security score

76/100

Risk levelLow

0–100, higher is better. How it is calculated

Novartis Poland operates as a regional branch of the global healthcare giant Novartis AG, providing innovative pharmaceutical solutions including oncology, rare disease treatments, and advanced therapies such as gene and cell therapy. The website reflects a mature digital presence with professional design, localized content in Polish, and integration of modern web technologies and analytics tools. The security posture is strong with HTTPS enforcement and cookie consent mechanisms, though some security headers and explicit incident response information are absent. WHOIS data is unavailable for the queried domain, which may be due to privacy protection or query limitations, but the website's branding and social media presence strongly support its legitimacy. Overall, the site demonstrates a high level of professionalism and compliance with privacy regulations.

Scanned

NIS2 and GDPR posture

GDPR outside view
65/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

5 findings rated critical or high. Fix these first.

  1. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

  2. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Privacy Policy found

      GDPR requires a clear and accessible privacy policy

      What to do: Add a comprehensive privacy policy page and link to it prominently

    • High

      Third-party services without privacy policy

      Detected services: Google Analytics, Facebook, Twitter, LinkedIn, YouTube, Cloudflare

      What to do: Document all third-party data sharing in your privacy policy

  3. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1
    • High

      Weak SSL Key Length

      SSL certificate uses 256-bit key, which is considered weak

      What to do: Use at least 2048-bit RSA or 256-bit ECC key

      • CWE-326
      • OWASP A04:2025
      • Mozilla TLS: Mozilla Server Side TLS 6.0 intermediate: rsa_key_size 2048

Need hands-on remediation? Email guard@offseq.com

Keep watching novartis.pl

This scan found 17 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. See sample alerts.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
57
Security headers
65
Email security
85
DNS health
85
Network security
100
GDPR outside view
65
Average
76

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Novartis Poland is positioned as an essential healthcare entity within the pharmaceutical sector, targeting patients, healthcare professionals, and stakeholders in Poland and globally. The business model focuses on innovative medicine development and delivery, supported by a strong parent company and subsidiaries like Sandoz. The website's content and structure indicate a focus on transparency, patient engagement, and regulatory compliance. The use of advanced analytics and marketing tools suggests a data-driven approach to customer engagement and market expansion. The absence of direct contact details on the main page may indicate reliance on other channels or localized contact points.

Security posture

The website employs HTTPS with a good SSL configuration and integrates cookie consent tools compliant with GDPR. However, the absence of visible security headers such as Content Security Policy, HSTS, and X-Frame-Options represents an area for improvement. No vulnerabilities or exposed sensitive data were detected in the analyzed content. The lack of a published security policy or incident response contact reduces transparency in security governance. Overall, the security posture is solid but could be enhanced by adopting additional best practices and publishing security-related information.

Recommendations

  1. Implement and verify HTTP security headers including CSP, HSTS, X-Frame-Options, and X-XSS-Protection.
  2. Publish a dedicated security policy page and provide incident response contact information.
  3. Add a security.txt file or vulnerability disclosure policy to facilitate responsible reporting.
  4. Enhance transparency by including clear company contact information on the website.
  5. Regularly audit third-party scripts and tracking tools to minimize privacy and security risks.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Novartis Poland
Description
Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
Key services
Innovative medicines, Oncology drug development, Rare disease treatment, Cell therapy, Gene therapy
Content quality
excellent
Branding
consistent

Technology

Stack
Drupal CMS, Font Awesome, Google Tag Manager, Crazy Egg, AddToAny, Litepicker (date picker library), Day.js
Frameworks
Drupal
Performance
moderate
Mobile
excellent
Accessibility
good
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent mechanism
  • No exposed sensitive data in HTML

Analytics and tracking

Services
Google Tag Manager, Crazy Egg
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Crazy Egg
Marketing tools
Crazy Egg, AddToAny
Transparency
good

Site quality

Design
excellent
User experience
excellent
Content relevance
excellent
Navigation
excellent
Professionalism
excellent
Trustworthiness
high

Key observations

  1. Website is a professional corporate site for Novartis Poland, a global healthcare company.
  2. Content is in Polish language with localized regional targeting.
  3. Site uses Drupal CMS with modern JavaScript libraries and tracking tools.
  4. Privacy and cookie policies are present and GDPR compliant.
  5. No contact emails or phone numbers explicitly found in the provided HTML snippet.
  6. No security.txt or explicit vulnerability disclosure found.
  7. WHOIS data is missing or inaccessible for the queried domain.
  8. No WAF or blocking detected; site content fully accessible.
  9. Site uses HTTPS with good SSL configuration.
  10. Social media presence is linked with official Novartis accounts.
Technical notes

Notes

The website is built on Drupal CMS, leveraging modern JavaScript libraries such as Day.js and Litepicker for enhanced user experience. It integrates multiple analytics and marketing tools including Google Tag Manager and Crazy Egg, indicating a mature digital marketing strategy. The site is mobile-optimized with responsive design and accessibility features. Performance is moderate, with potential for optimization in loading speed. The technical infrastructure appears robust, but the absence of some security headers and explicit hosting provider information suggests areas for further technical hardening and transparency.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with novartis.pl. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review novartis.pl.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.